10-Q: Exagen Inc. Reports Q2 2026 Revenue Growth, Margin Improvement

Exagen Inc. announced a 15.9% increase in revenue for the second quarter of 2026, driven by higher test volumes and an expanded AVISE CTD platform, alongside improved gross margins.

Summary

• Exagen Inc. reported revenue of $19.94 million for the three months ended June 30, 2026, a 15.9% increase from $17.20 million in the same period of 2025.
• For the six months ended June 30, 2026, revenue was $37.25 million, up 13.9% from $32.70 million in the prior year.
• Gross profit for the second quarter of 2026 was $12.22 million, an increase from $10.40 million in Q2 2025, with gross margin improving to 61.3% from 60.4%.
• Net loss for the second quarter of 2026 was $3.20 million, an improvement from a net loss of $4.44 million in Q2 2025.
• The company had $24.59 million in cash and cash equivalents as of June 30, 2026, with an accumulated deficit of $321.45 million.
• Management believes current capital resources are sufficient for at least the next twelve months, but may require additional funding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic outlook, with revenue growth and improved gross margins, but persistent net losses and a need for future funding remain key concerns.

Positives

• Revenue increased by 15.9% to $19.94 million in Q2 2026 compared to Q2 2025.
• The number of AVISE CTD tests delivered increased by approximately 11% in Q2 2026 compared to Q2 2025.
• Average Selling Price (ASP) for AVISE CTD tests increased by 4% to $446 per test in Q2 2026.
• Gross margin improved to 61.3% in Q2 2026 from 60.4% in Q2 2025.
• Pharma services revenue increased by approximately $0.7 million in Q2 2026 compared to Q2 2025.
• Net loss improved to $3.20 million in Q2 2026 from $4.44 million in Q2 2025.

Negatives

• The company incurred a net loss of $3.20 million in Q2 2026 and $7.16 million for the first six months of 2026.
• The company has an accumulated deficit of $321.45 million as of June 30, 2026.
• Cash and cash equivalents decreased to $24.59 million as of June 30, 2026, from $32.22 million as of December 31, 2025.
• Operating expenses increased by $0.91 million to $13.94 million in Q2 2026 compared to Q2 2025.
• Interest expense increased by $0.1 million in Q2 2026 compared to Q2 2025, primarily due to the Perceptive Term Loan Facility.

Risks

• The company has incurred recurring losses and negative cash flows from operating activities since inception and anticipates continuing net losses.
• Management believes existing capital resources are sufficient for at least twelve months, but additional funding may be needed, and there is no assurance it will be obtained on acceptable terms.
• Failure to obtain or maintain coverage and adequate reimbursement from third-party payors could hinder revenue growth.
• Changes in U.S. trade policy, including tariffs, could increase costs for imported reagents and materials.
• The current inflationary environment may continue to impact costs and financial condition.
• The company is dependent on key suppliers for certain laboratory materials, and an interruption in supply could impact testing services.
• The process for obtaining and maintaining consistent reimbursement for new tests can be uncertain, lengthy, and time-consuming.

Future Outlook

Management believes current capital resources are sufficient for at least the next twelve months. However, the company anticipates continued net losses and may require additional funding to support operations and growth strategies. The company expects moderate increases in operating expenses in the near term due to sales force expansion and infrastructure investment, but anticipates SG&A expenses to decrease as a percentage of revenue year-over-year. R&D expenses are expected to increase moderately in absolute dollars due to pipeline initiatives but decrease as a percentage of revenue.

Management Comments

• Under the leadership of our Chief Executive Officer, John Aballi, who joined Exagen in October 2022, we have executed an operational turnaround of the business, resulting in a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn.
• We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.
• We strive to become a partner of choice for doctors, hospitals, healthcare systems, and payors.

Industry Context

StockSavvy.ai notes that Exagen operates in the competitive diagnostics market, focusing on complex autoimmune diseases. The company's strategy of enhancing its AVISE CTD platform with new biomarkers and expanding pharma partnerships aligns with industry trends towards more personalized and precise diagnostics. However, the reliance on third-party payor reimbursement and the lengthy process for obtaining coverage remain significant industry-wide challenges.

Comparison to Industry Standards

• The company's gross margin of 61.3% in Q2 2026 is a key performance indicator in the diagnostics sector. While specific industry benchmarks for companies of Exagen's size and specialization are not readily available, maintaining or improving this margin is crucial for profitability.
• The reported net loss of $3.2 million for the quarter, while an improvement, highlights the capital-intensive nature of diagnostic development and commercialization, a common characteristic across the industry.
• Exagen's focus on specific autoimmune diseases like SLE and RA places it within a niche of the broader diagnostics market. Competitors in this space often include larger, more diversified diagnostic companies as well as specialized players.

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings if additional capital is raised. Continued net losses may impact investor sentiment.
• Creditors: The company has significant debt obligations under the Perceptive Term Loan Facility, with covenants that restrict certain actions.
• Suppliers: The company has minimum purchase commitments under an amended supply agreement, impacting supplier relationships.
• Customers (Healthcare Providers): Continued focus on providing clinically useful diagnostic tools to aid in patient care and decision-making.

Next Steps

• Continue to enhance the AVISE CTD platform with new biomarkers.
• Pursue additional partnerships with pharmaceutical companies and academic research centers.
• Focus on optimizing revenue cycle practices and expanding medical policy coverage for testing products.
• Continue research and development for new testing products, including Myositis, Lupus Nephritis, SLE Disease Activity, and RA Disease Activity.
• Launch first Myositis offering in 2027.
• Continue efforts to release Lupus Nephritis (LN) offering commercially.

Key Dates

Recommendation

Exagen Inc. shows positive revenue and gross margin trends, indicating operational improvements. However, the persistent net losses, substantial accumulated deficit, and the acknowledged need for potential future capital raises present significant risks. While the company is executing on its strategy, the path to profitability remains uncertain, warranting a 'hold' recommendation until more sustainable financial performance is demonstrated.

Keywords

AVISE CTD, autoimmune disease, rheumatology, diagnostic testing, biomarkers, revenue growth, net loss, financial condition